Phase i pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: A children's oncology group phase i consortium report

Journal of Clinical Oncology

Volumn 31, Issue 24, 2013, Pages 3034-3043

  Bender, Julia L Glade ^a   Lee, Alice ^a   Reid, Joel M ^b   Baruchel, Sylvain ⁱ   Roberts, Timothy ^d   Voss, Stephan D ^e   Wu, Bing ⁱ   Ahern, Charlotte H ^f   Ingle, Ashish M ^g   Harris, Pamela ^h   Weigel, Brenda J ^c   Blaney, Susan M ^f  

^a NewYork Presbyterian Hospital   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f TEXAS CHILDREN S CANCER CENTER   (United States)

^g CHILDREN S ONCOLOGY GROUP   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; ENDOGLIN; PAZOPANIB; PLACENTAL GROWTH FACTOR; TRIACYLGLYCEROL LIPASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ACCUMULATION INDEX; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALVEOLAR SOFT PART SARCOMA; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATYPICAL TERATOID RHABDOID TUMOR; BACKACHE; BLEEDING; BODY WEIGHT DISORDER; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD CANCER; CLEAR CELL SARCOMA; CONCENTRATION AT STEADY-STATE; CONFERENCE PAPER; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; ELIMINATION HALF-LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPENDYMOMA; EWING SARCOMA; FATIGUE; FEMALE; FISTULA; GENE EXPRESSION; GERM CELL TUMOR; GLIOMA; GROWTH DISORDER; HAND FOOT SYNDROME; HEADACHE; HEPATOBLASTOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROBLASTOMA; NEUROECTODERM TUMOR; NEUTROPENIA; NEUTROPHIL COUNT; OSTEOSARCOMA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIMITIVE NEUROECTODERMAL TUMOR; PRIORITY JOURNAL; PROTEINURIA; RHABDOMYOSARCOMA; SIDE EFFECT; SINUS BRADYCARDIA; SOFT TISSUE SARCOMA; SOLID MALIGNANT NEOPLASM; SYNOVIAL SARCOMA; TABLET FORMULATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE NECROSIS; TREATMENT RESPONSE; TUMOR PAIN; VOMITING; ARTICLE; BLOOD; DISEASE FREE SURVIVAL; METABOLISM; NEOPLASM; PRESCHOOL CHILD; SARCOMA;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASMS; PYRIMIDINES; SARCOMA; SULFONAMIDES; YOUNG ADULT;

EID: 84887241696     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.0914     Document Type: Conference Paper

References (29)

1. Kumar R, Knick VB, Rudolph SK, et al: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012-2021, 2007
2. Keir ST, Morton CL, Wu J, et al: Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 59:586-588, 2012
3. Kumar S, Mokhtari RB, Sheikh R, et al: Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17:5656-5667, 2011
4. Sleijfer S, Ray-Coquard I, Papai Z, et al: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 27:3126-3132, 2009
5. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
6. van der Graaf WT, Blay JY, Chawla SP, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebocontrolled phase 3 trial. Lancet 379:1879-1886, 2012
7. Heath EI, Forman K, Malburg L, et al: A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs 30:1566-1574, 2012
8. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576, 2004
9. Fox E, Aplenc R, Bagatell R, et al: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28:5174-5181, 2010
10. Skolnik JM, Barrett JS, Jayaraman B, et al: Shortening the timeline of pediatric phase I trials: The rolling six design. J Clin Oncol 26:190-195, 2008
11. Goh BC, Reddy NJ, Dandamudi UB, et al: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652-659, 2010
12. Mancuso P, Burlini A, Pruneri G, et al: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661, 2001
13. Glade Bender JL, Adamson PC, Reid JM, et al: Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 26:399-405, 2008
14. Demsar F, Roberts TP, Schwickert HC, et al: A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution. Magn Reson Med 37:236-242, 1997
15. Hurwitz HI, Dowlati A, Saini S, et al: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220-4227, 2009
16. Heath EI, Chiorean EG, Sweeney CJ, et al: A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 88:818-823, 2010
17. Aziz R, Helms W: Votrient (pazopanib hydrochloride) tablets. Pharmacology review (NDA 22465). US Food and Drug Administration. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2009/022465s000TOC. cfm
18. Suttle B, Ball H, Molimard M, et al: Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). J Clin Oncol 28:245s, 2010 (suppl; abstr 3048)
19. Scartozzi M, Galizia E, Chiorrini S, et al: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227-230, 2009
20. Rini BI, Cohen DP, Lu DR, et al: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773, 2011
21. George S, Reichardt P, Lechner T, et al: Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 23:3180-3187, 2012
22. Nikolinakos PG, Altorki N, Yankelevitz D, et al: Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70:2171-2179, 2010
23. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
24. Hahn OM, Yang C, Medved M, et al: Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572-4578, 2008
25. Gerber HP, Vu TH, Ryan AM, et al: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628, 1999
26. Broniscer A, Baker JN, Tagen M, et al: Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 28:4762-4768, 2010
27. Dubois SG, Shusterman S, Ingle AM, et al: Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group study. Clin Cancer Res 17:5113-5122, 2011
28. Glade Bender J, Yamashiro DJ, Fox E: Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist 16:1614-1625, 2011
29. Glade Bender J, Blaney SM, Borinstein S, et al: A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: A Children's Oncology Group phase I consortium report. Clin Cancer Res 18:5081-5089, 2012